ZITUVIMET XR Drug Patent Profile
✉ Email this page to a colleague
When do Zituvimet Xr patents expire, and when can generic versions of Zituvimet Xr launch?
Zituvimet Xr is a drug marketed by Zydus Lifesciences and is included in one NDA.
The generic ingredient in ZITUVIMET XR is metformin hydrochloride; sitagliptin. There are forty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZITUVIMET XR?
- What are the global sales for ZITUVIMET XR?
- What is Average Wholesale Price for ZITUVIMET XR?
Summary for ZITUVIMET XR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| What excipients (inactive ingredients) are in ZITUVIMET XR? | ZITUVIMET XR excipients list |
| DailyMed Link: | ZITUVIMET XR at DailyMed |
Pharmacology for ZITUVIMET XR
| Drug Class | Biguanide Dipeptidyl Peptidase 4 Inhibitor |
| Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
US Patents and Regulatory Information for ZITUVIMET XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences | ZITUVIMET XR | metformin hydrochloride; sitagliptin | TABLET, EXTENDED RELEASE;ORAL | 216778-002 | Jul 18, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Lifesciences | ZITUVIMET XR | metformin hydrochloride; sitagliptin | TABLET, EXTENDED RELEASE;ORAL | 216778-003 | Jul 18, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Lifesciences | ZITUVIMET XR | metformin hydrochloride; sitagliptin | TABLET, EXTENDED RELEASE;ORAL | 216778-001 | Jul 18, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
